Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.

Blood Adv · 2023 · PMC10709678 · PMID 37722354

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

21 , 24 Although there was a numerical trend in PFS favoring ibrutinib + CIT, the study was not adequately powered to allow for a formal statistical comparison, given the small number of patients with MZL.

also in 268 other papers

a positive trendno p-value reported

Although a positive trend favoring the ibrutinib + CIT arm was observed for PFS up to ∼36 months, the P value efficacy boundary of .0476 was not crossed; therefore, the primary end point was not met.

also in 3,891 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.